Skip to content
Clinical Trials – home
Therapeutic area

Reproductive system and breast disorders – page 43

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer

Not yet recruiting

Study on the Effectiveness of Trastuzumab, Pertuzumab, and Docetaxel for Patients with Early HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:HUS-Yhtymae

Infertility female

Not yet recruiting

Study of testosterone gel treatment for women with low ovarian reserve and androgen receptor polymorphism undergoing fertility treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Instituto Bernabeu S.L.

Cervix carcinoma+2

Not yet recruiting

Study on the Effectiveness of Carboplatin and Paclitaxel in Treating Cervical Cancer with Para-aortic Lymph Node Involvement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Endometrial cancer+3

Not yet recruiting

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Gastric cancer+2

Not yet recruiting

Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Study Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Academisch Ziekenhuis Maastricht

Breast cancer female

Not yet recruiting

Study on the Use of Iomeprol in Contrast Enhanced Mammography for Identifying Breast Cancer in Patients with BIRADS 4 or 5 Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Iomeprol
  • Sponsor:Azienda Ospedaliero-Universitaria Policlinico Umberto I

Malignant peritoneal neoplasm+2

Not yet recruiting

Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Agencja Badań Medycznych

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Cannabidiol for Joint Pain in Early Breast Cancer Patients on Hormone Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cannabidiol
  • Sponsor:Institut Gustave Roussy

Breast cancer

Not yet recruiting

Study on the Effectiveness of Ropivacaine Hydrochloride, Anhydrous Lidocaine Hydrochloride, and Alfentanil for Patients Undergoing Minor Breast Cancer Surgery

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Lidocaine Hydrochloride
  • Sponsor:Region Sjaelland

Endometriosis

Not yet recruiting

Study on Cabergoline for Pain and Fertility in Women with Endometriosis and Infertility

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Cabergoline
  • Sponsor:Turku University Hospital

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.